Medical Patent Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Sigma-Aldrich

Recent developments reported by Sigma-Aldrich

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Sigma-Aldrich.

Report 1: Sigma-Aldrich (SIAL) announced an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize its TransPlex whole transcriptome amplification (WTA) technology.

The TransPlex technology is a fast, sensitive method for amplifying total RNA from a variety of sample sources such as animals, plants, and microorganisms. Under the terms of the agreement, Rubicon retains all rights to TransPlex for molecular diagnostics.

...

• View Other Issues of Medical Patent Law Weekly
  
• View Other NewsRx Publications